Literature DB >> 18504333

Application of the screening for Heart Attack Prevention and Education Task Force recommendations to an urban population: observations from the Dallas Heart Study.

Raphael See1, Jason B Lindsey, Mahesh J Patel, Colby R Ayers, Amit Khera, Darren K McGuire, Scott M Grundy, James A de Lemos.   

Abstract

BACKGROUND: The Screening for Heart Attack Prevention and Education (SHAPE) Task Force recommends noninvasive atherosclerosis imaging of all asymptomatic men (aged 45-75 years) and women (aged 55-75 years), except those at very low risk, to augment conventional cardiovascular risk assessment algorithms.
METHODS: Among 2611 participants in the Dallas Heart Study aged 30 to 65 years who underwent computed tomography to measure coronary artery calcification, low-density lipoprotein cholesterol (LDL-C) therapeutic targets were calculated using both National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and SHAPE algorithms. The proportion of subjects reclassified as being "at goal" for LDL-C vs "not at goal" after implementation of the SHAPE recommendations was determined.
RESULTS: More subjects were identified with LDL-C levels greater than or equal to goal based on SHAPE than on NCEP-ATP III (27.4% vs 21.6%), with 7.0% of individuals reclassified as having unmet LDL-C goals and 1.1% of individuals reclassified as at goal. When more aggressive optional LDL-C goals were implemented, 31.7% had LDL-C levels greater than or equal to goal using SHAPE recommendations vs 28.1% using NCEP-ATP III recommendations, with 6.3% of subjects reclassified as being not at goal and 2.7% as being at goal.
CONCLUSIONS: The SHAPE recommendations resulted in bidirectional reclassification of eligibility for lipid-lowering therapy in subjects aged 30 to 65 years. While broad implementation of these recommendations would modestly increase cholesterol-lowering drug use in this age range, the magnitude of the increase depends on whether standard or optional LDL-C goals are targeted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18504333     DOI: 10.1001/archinte.168.10.1055

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

1.  Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death.

Authors:  Marie-Luise Brennan; Anupama Reddy; W H Wilson Tang; Yuping Wu; Danielle M Brennan; Amy Hsu; Shirley A Mann; Peter L Hammer; Stanley L Hazen
Journal:  Circulation       Date:  2010-06-21       Impact factor: 29.690

2.  Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.

Authors:  James A de Lemos; Mark H Drazner; Torbjorn Omland; Colby R Ayers; Amit Khera; Anand Rohatgi; Ibrahim Hashim; Jarett D Berry; Sandeep R Das; David A Morrow; Darren K McGuire
Journal:  JAMA       Date:  2010-12-08       Impact factor: 56.272

Review 3.  Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.

Authors:  Richard Kones
Journal:  Drug Des Devel Ther       Date:  2011-06-13       Impact factor: 4.162

4.  Lipid profiles and trans fatty acids in serum phospholipids of semi-nomadic Fulani in northern Nigeria.

Authors:  Robert H Glew; Lu-Te Chuang; Tammy Berry; Henry Okolie; Michael J Crossey; Dorothy J VanderJagt
Journal:  J Health Popul Nutr       Date:  2010-04       Impact factor: 2.000

5.  Evaluation of coronary artery calcium screening strategies focused on risk categories: the Dallas Heart Study.

Authors:  Mahesh J Patel; James A de Lemos; Darren K McGuire; Raphael See; Jason B Lindsey; Sabina A Murphy; Scott M Grundy; Amit Khera
Journal:  Am Heart J       Date:  2009-06       Impact factor: 4.749

Review 6.  Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome.

Authors:  Helen H Wang; Dong Ki Lee; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2020-05-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.